November 4, 2011
In its business results briefing on November 2, President & Representative Director Toshio Asano of Asahi Kasei Pharma revealed that the company plans to initiate a PIII clinical trial in Japan of the bisphosphonate (BP) zoledronic acid at the beginning...read more